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Abstract: The present report shows that nicotine enhances some of alcohol’s positive and 
negative effects in women and that these effects are most pronounced during the luteal 
phase of the menstrual cycle. Ten low progesterone and 10 high progesterone/luteal-phase 
women received nicotine patch pretreatments (placebo or 21 mg) 3 hours before an alcohol 
challenge (0.4 g/kg). Subjective effects were recorded on mood adjective scales and the 
Addiction Research Center Inventory (ARCI). Heart rate and skin temperature were 
recorded. Luteal-phase women reported peak positive (e.g. “stimulated”) and peak negative 
effects (e.g. “clumsy”, “dizzy”) almost twice as great as low progesterone women.  
Keywords: Transdermal nicotine; alcohol; subjective effects; menstrual cycle; 
progesterone. 
 
1. Introduction 
 
The concurrent use of tobacco with alcohol is one of the most common drug combinations in the 
United States. There is a general consensus that nicotine modifies the acute effects of alcohol. This 
relationship is likely to be state- and dose-related as nicotine administration has been shown to result in 
both antagonism and synergism of alcohol’s effects [1-3]. Human laboratory studies designed to 
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explore the nature of this interaction have frequently focused on how alcohol affects tobacco smoking 
or nicotine’s effects [3-7]. Mitchell et al. [8] demonstrated that alcohol consumption increases the 
number of cigarettes smoked in a controlled laboratory setting, but only shortly after drinking when 
blood alcohol levels were rising. Although Zacny et al. [9] demonstrated that alcohol did not increase 
tobacco cigarette preference over a money reinforcer, Burton and Tiffany [4] did show that alcohol 
intoxication increased cravings to smoke. The reverse situation of how nicotine affects alcohol intake 
has also been studied, but to a lesser extent [10, 11].  
Acute administration of nicotine has been shown to potentiate the discriminative stimulus properties 
of ethanol in rats [12] and continuous administration of nicotine increases ethanol drinking by rats [13, 
14]. With human subjects, Perkins et al. [3] showed that nicotine delivered intranasally increased 
alcohol’s subjective stimulating and cardiovascular effects. The subjective effects were noted when 
blood alcohol levels were rising shortly after drinking. Once drinking began, nicotine was found to 
reverse the sedating effects of alcohol during decreasing blood alcohol levels. The reversal of alcohol’s 
sedating effects was particularly prominent in men while the increased stimulating effects were more 
prominent in women (see also review in [15]). Kouri et al. [16] found that nicotine pretreatment via 
the transdermal patch enhanced both the subjective and cardiovascular effects of ethanol in men. 
Reports of feeling drunk and ethanol-induced euphoria, among other measures, were more prominent 
when subjects were pretreated with a 21 mg transdermal nicotine patch compared to placebo. Heart 
rate increases following drinking also were greater with nicotine pretreatment. The finding that 
tobacco smoking and alcohol consumption are positively correlated [17-20] has important health-
related consequences, not only from the perspective of combined morbidity after chronic use and 
abuse, but may be important mediating factors in the initiation of using other drugs, particularly in 
adolescents. 
Important sex-related differences in the effects of nicotine have been noted. In general, nicotine 
appears to be less of a reinforcer for maintaining cigarette smoking in women than in men [21] and this 
may be due to sex differences in the sensitivity to nicotine’s interoceptive cues [22]. Menstrual cycle 
hormones are important factors for understanding many drug effects  in women. For example, 
responses to cocaine and amphetamine are influenced by varying estrogen and progesterone levels 
associated with the follicular and luteal phases [23-26]. Subjective responses to these drugs generally 
were reduced during the luteal phase of the cycle. In addition, drug intake has been shown to vary 
throughout the menstrual cycle. Both alcohol and nicotine use has been found to be greater during the 
luteal phase of the cycle [27-29], although this may not be a consistent effect with nicotine [30, 31]. 
Mello et al. [32], while examining cigarette smoking and alcohol self-administration in women, found 
that nearly three-quarters of women increased smoking during the late luteal phase of their menstrual 
cycle, as measured by inter-cigarette interval. Additional evidence for the influence of menstrual cycle 
phase on nicotine’s effects is seen during withdrawal. Perkins et al. [33] report that the severity of 
nicotine  withdrawal symptoms is greater during the luteal (premenstrual) phase of the cycle than 
during the follicular, which may explain why others have reported more smoking during this phase 
[27, 34]. 
Nicotine administered by cigarette smoking has a relatively short duration of action. Peak blood 
nicotine levels are achieved typically within the time it takes to consume the cigarette (5 to 10 Int. J. Environ. Res. Public Health 2009, 6          
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minutes) and decline quickly [35]. Alcohol, however, via the oral route, has a slower onset and longer 
duration of action. Therefore, in the present study, transdermal nicotine was used for several reasons. 
First, in an effort to study nicotine-alcohol interactions over a more sustained period of time, a steady-
state of nicotine levels (as can be supplied by the patch) was desired for the duration of the assessment 
period. Second, cigarette smoking involves a host of other factors (sensations of taste, olfaction, intake 
of other chemicals, and strongly conditioned behaviors) that may interact with alcohol and the 
behavior of drinking, and thus affect subjective experiences. Third, with the availability of the nicotine 
patch over-the-counter, and the health and societal emphasis to restrict smoking, there is great 
likelihood that nicotine in forms other than smoked cigarettes (patch, smokeless tobacco, gum, and 
lozenge) will be used in conjunction with common drugs of abuse. Previous reports from our 
laboratory have shown that nicotine can enhance the subjective and physiological effects of marihuana 
in both men and women [36], of ethanol in men [16], and can attenuate the effects of cocaine [37]. The 
goals of the present study were to explore the effects of nicotine directly, unencumbered by the 
complexities of cigarette smoking, on alcohol’s subjective and physiological effects in women, and to 
examine the influences of progesterone on these effects. Our hypotheses were that nicotine 
pretreatment would alter alcohol’s effects and these effects would be further modulated by 
progesterone levels in women.  
 
2. Experimental Section 
 
Participants. Female participants were recruited from the Boston metropolitan area via newspapers, 
flyers and Internet advertisements. To be considered for the study, subjects had to be between the ages 
of 21 and 35 years old with a body mass index (BMI) between 18 and 25, report during an initial 
telephone interview regular smoking of at least five cigarettes per day and drinking at least four 
alcoholic drinks per week. Following the telephone interview, qualifying potential subjects were 
scheduled for a physical examination and a psychological evaluation in the laboratory. To qualify, 
subjects had to have a normal physical examination and electrocardiogram, have normal blood 
chemistry and urinalysis, have no current alcohol or other drug dependence (except nicotine 
dependence) according to DSM-IV criteria, have no major psychiatric disorder according to DSM-IV 
criteria (including depression), and report a negative maternal and paternal history of alcohol 
dependence. Subjects who met DSM-IV criteria for current or past alcohol abuse (but not dependence) 
were accepted. Subjects were excluded if they met DSM-IV criteria for premenstrual dysphoric 
disorder (PMDD), had a history of major head trauma, were hepatitis positive, or were regularly taking 
prescription medications (except oral birth control pills). Those women taking oral contraceptive 
medication (see below) had to be taking a combination type pill (estrogen plus progesterone); 
progesterone only pill-taking women were excluded. Information about those completing the study is 
presented in Table 1. For the duration of the study, all women kept track of their menstrual cycle with 
a daily menstrual calendar that included the start and stop dates of menses. The protocol and informed 
consent were reviewed and approved by the McLean Hospital Institutional Review Board. Participants 
were paid for their participation.  
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Table 1. Demographic and Drug Use Information (averages ± sd). There were no 
significant differences between groups on any demographic or drug use variable. Caffeine 
use was defined as the number of 100 mg drinks per day. FTND: Fagerstrom Test for 
Nicotine Dependence.  
 
Age 
(years) 
Cigarettes 
per Day 
FTND 
Score 
Caffeine 
Use 
(drinks/day)
Alcohol 
drinks 
per 
week 
Met 
Criteria 
for 
Current 
or past 
Alcohol 
Abuse 
Progesterone 
Levels on 
Study Days* 
(ng/mL) 
Low 
Progesterone 
22.3±1.5 15.3±4.7 4.2±1.1 1.90±0.94 8.8±5.8 3  M=0.65±0.32 
MDN=0.6 
High 
Progesterone 
(Luteal-
phase 
women) 
24.1±2.8 14.2±3.2 4.0±1.3 2.25±1.64 11.2±5.6 5 
 
M=7.14±4.33 
MDN=7.45 
* Significantly different averages between groups, p<.001. M=mean (average) value; MDN=median value. 
 
Experimental design. This study was a 3-visit, randomized dosing study investigating the effects of 
a 21 mg nicotine patch pretreatment versus a placebo patch on the subjective and physiological effects 
of an alcohol challenge (0.4 g/kg). The three conditions presented in a randomized order were: nicotine 
alone (21 mg nicotine patch and placebo drink), alcohol alone (placebo patch and 0.4 g/kg alcoholic 
drink), and a combination of both drugs (21 mg nicotine patch and 0.4 g/kg alcoholic drink). Two 
groups were studied: 10 women taking oral contraceptives who had progesterone levels of less than 1.9 
ng/mL and 10 women not taking oral contraceptives who were in the luteal phase of their menstrual 
cycle. A blood sample was taken on every study day for serum progesterone levels to verify menstrual 
cycle phase (Quest Diagnostics, Cambridge, MA). For the low progesterone level women, study days 
were scheduled between days five and 10 of their cycle (Day 1 was the first day of menstruation). 
Their average progesterone levels on study days were 0.65±0.32 ng/mL (range: <0.3 – 1.9 ng/mL) 
(Table 1). Luteal participants used non-hormonal methods of contraception and kept track of their 
cycles through the use of a commercial ovulation kit (Answer One-Step Ovulation Test Kit). The study 
was scheduled to occur seven (7) to 13 days after ovulation (between days 21 and 27 of the menstrual 
cycle). Their average progesterone levels on study days were 7.14±4.33 ng/mL (range: 0.8 – 16 
ng/mL). For each participant, study days occurred on or about the same day of their monthly menstrual 
cycle and thus took at least 3 months to complete all drug conditions.  
Study Day. Participants were required to abstain from using all illicit drugs and alcohol for 72 and 
24 hours, respectively, prior to the study. Participants could not smoke cigarettes, have any caffeine, 
eat or drink liquids (excluding water) from midnight prior to each study day. If they failed to comply 
with these restrictions, the study day was rescheduled. Participants arrived at the laboratory at 8:00 Int. J. Environ. Res. Public Health 2009, 6          
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a.m. at which time they provided breath samples to check for the presence of alcohol (AlcoSensor, 
Intoximeter, Saint Louis, MO) and carbon monoxide as a measure of whether they complied with the 
smoking restrictions (Vitalograph, Lenexa, KS). Breath alcohol levels (BAL) had to be below 0.002% 
and expired air had to be below 14 ppm carbon monoxide for subjects to participate that day. A urine 
sample had to be negative for illicit drugs (Biosite Diagnostics, San Diego, CA) and pregnancy 
(QuPID, Stanbio Laboratory, Boerne, TX). All subjects met these study restrictions at every visit and 
no session had to be rescheduled due to failure to meet these study restrictions.  
 
Nicotine pretreatment. Immediately following these evaluations, participants were taken into a 
dormitory-like room (equipped with a recliner chair, television, and stereo), fitted with skin 
temperature and heart rate devices for continuous monitoring (Mini Logger
® Series 2000; Mini Mitter 
Co., Bend, OR) and given a series of paper and pencil questionnaires to assess mood. Mood was 
assessed through the use of the Addiction Research Center Inventory (ARCI) [38] and visual analog 
scale (VAS) questionnaires. A research assistant then applied either a 21 mg nicotine (NicoDerm
® CQ, 
SmithKline Beecham) or placebo patch to the back of their upper arm. Placebo patches consisted of a 
nicotine patch without the plastic backing removed. All identifying markings were masked before a 
patch was used. Participants were provided a light breakfast (toast and juice) and for the first 2.5 hours 
of the study, participants were able to read, watch TV, or listen to music while relaxing in a recliner 
chair. At 30 minute intervals, the participants completed the ARCI and VAS questionnaires, and their 
blood pressure was taken. After 2.5 hours of nicotine pretreatment, participants were taken into a 
sound and light attenuated room equipped with a wired intercom and a closed circuit camera that 
provided auditory and visual contact with the participants. Each participant relaxed in a recliner chair 
where they were connected to an electrocardiogram machine, blood pressure cuff, and a skin 
temperature thermister. A catheter was inserted into an antecubital vein for blood collection using an 
integrative sampling procedure [39]. 
 
Acute alcohol challenge. Exactly three hours after the application of the nicotine or placebo patch, 
participants drank either an alcoholic drink or a placebo drink. The 400 mL alcoholic drink consisted 
of chilled orange juice mixed with a name brand vodka (80 proof) to a dose of 0.4 g/kg which was 
divided into 3 cups. (The drink is comparable to approximately two typical alcoholic drinks). The 
placebo drink consisted of three cups filled with an equivalent amount of juice. A small amount of 
vodka (0.25 mL) was placed on the surface of the juice and the rims of the glasses were swabbed with 
vodka to mask the taste of the placebo drink. When instructed, participants began drinking and were 
given five minutes to finish each cup, for a total of a 15-minute alcohol administration period. Fifteen 
minutes after alcohol administration was complete (30 minutes post-onset of drinking), blood pressure 
was taken, participants were asked to answer a set of questionnaires using a keypad, and then were 
asked to give a breath sample to measure alcohol concentration levels. Every thirty minutes thereafter, 
participants had their blood pressure taken, were asked to answer questionnaires (ARCI, VAS) and 
give a breath sample. Three hours after the beginning of the drinking session, the participants were told 
the study was over, were given lunch, and then sent home in a cab. Breath alcohol concentration levels 
had to be below 20 mg/dL (0.02%) before the participants were allowed to leave the laboratory. All 
participants were transported to and from the laboratory by taxicab. Int. J. Environ. Res. Public Health 2009, 6          
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Subjective measures. On 12 separate occasions during each study day (every 30 minutes from 
baseline through the end of the session), participants were administered the Addiction Research Center 
Inventory (ARCI) and a set of Visual Analog Scales (VAS). The 49-item ARCI questionnaires were 
scored to give ratings on MBG (morphine/benzedrine  group-euphoria), PCAG 
(pentobarbital/chlorpromazine/ alcohol group--sedation), AMP (amphetamine--stimulation), BG 
(benzedrine group--stimulation), and LSD (lysergic acid diethylamide--dysphoria and somatic effects) 
scales. Participants rated their response to the following 20 adjectives/phrases on a 100-point VAS 
from “not at all” to “extremely,”: happy, stimulated, anxious, clumsy, dizzy, drunk, great, high, 
muddled/confused, nauseous, terrible, sleepy, floating, slurred speech, uncomfortable, feel effects of 
alcohol, desire to use alcohol, desire not to use alcohol, desire to smoke a tobacco cigarette, and desire 
not to smoke a tobacco cigarette.  
Participants were also asked to report alcohol’s subjective effects on a continuous basis using a 
keypad device. Participants were instructed to press the key on the keypad labeled “euphoric” 
whenever they experienced feelings of intense well-being, good effects, or intense pleasure, and to 
press a key labeled “dysphoric” if they experienced intense bad feelings, bad effects, or discomfort. 
Participants were instructed to press the key labeled “detect” if at any point after the onset of the 
drinking session they felt the effects of alcohol, and to turn it off when they no longer felt the effects of 
alcohol. A computer screen in the experimental chamber provided participants with a record of their 
keypad report, and all three could be registered at the same time, if appropriate.  
 
Physiologic measures. Skin temperature (
oC) and heart rate (beats per minute or bpm) were 
recorded throughout the study using a Mini Logger
® Series 2000 device (Mini Mitter Co., Bend, OR). 
Skin temperature was recorded using single-use temperature probes (Steri-Probe, Cincinnati Sub-Zero 
Products, Cincinnati, OH) attached to the stomach area just below the lowest right rib and connected to 
a port in the logger. Heart rate was recorded via a Polar Co. chest belt sensor attached (via Cleartrace 
adult ECG electrodes; ConMed Corp., Utica, NY) to the left side of the participant’s chest below the 
heart. While in the chamber, participants also had a three-lead EKG (Lead III), and a blood pressure 
cuff attached to their right arm. Blood pressure was taken at 30-minute intervals either manually 
during the nicotine pretreatment period or with an automated sphygmomanometer (Hewett Packard 
78352A physiological recording device) during the alcohol challenge period.  
 
Blood sampling procedures/plasma analysis. An intravenous (i.v.) catheter (Kowarski-Dakmed 
Thromboresistant Blood Withdrawal Needle and 8 foot Tubing Set; Dakmed, Inc., Buffalo, NY) was 
inserted in an antecubital vein for withdrawal of blood samples after 2.5 hours of patch pretreatment 
and once the participant was taken into the experimental chamber. The distal end of the catheter was 
passed through an opening in the chamber wall and attached to a 10-mL syringe mounted on a 
withdrawal syringe pump at a rate of 1 mL/min. Syringes were changed every five minutes and the 
blood was put into Vacutainer
® tubes containing sodium fluoride and then placed on ice (see [39]). 
The blood samples were then centrifuged and the plasma was separated into a plastic vial and sent to 
Quest Diagnostics (Cambridge, MA) for quantitative ethanol analysis through gas chromatography. 
The sensitivity of the assay was 10 mg/dL with an intersample variation of 4.1%. Selected blood Int. J. Environ. Res. Public Health 2009, 6          
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samples were analyzed also for quantification of nicotine levels through gas chromatography by 
National Medical Services (Willow Grove, PA). The sensitivity of the assay was 5 ng/mL with an 
intrasample variation of 6.3% and an intersample variation of 9.7%. Blood samples used to verify 
progesterone levels were taken at the beginning of the study and were analyzed by Quest Diagnostics 
(Cambridge, MA).  
 
Data analysis. Dependent variables were analyzed using a repeated measures ANOVA (SPSS 11.0 
for Mac OS X). Dose and time were treated as within-subject factors and progesterone level (low vs. 
high) was treated as a between subjects factor. In order to facilitate and simplify analysis of the time 
course effects for the physiological data, separate analyses were performed on the nicotine 
pretreatment (before the drinking period) time points and then on the post-alcohol drinking time 
points. The post-drinking analysis included the baseline (-200 minute data).  Analysis of the peak 
subjective and physiologic responses was performed using a repeated measures ANOVA. Again, dose 
and time were treated as a within-subjects factor and progesterone level was treated as a between 
subjects factor. Following the identification of a main effect, Fisher’s Least Significant Differences 
post-hoc tests were performed to identify where significant time point or dose effects occurred. 
Statistical significance was set at p≤ 0.05. 
 
3. Results 
 
3.1. Effects following pretreatment with nicotine patch 
 
Nicotine was without effect on the subjective measures but did produce a significant elevation in 
heart rate (statistical analysis results for the physiological measures are reported in Table 2). There 
were no group differences at baseline (before nicotine patch application). Shortly after the nicotine 
patch application (within 20 minutes), heart rates increased significantly over baseline conditions and 
remained elevated for the duration of the pretreatment period. Average increases ranged from 9-15 
beats per minute (bpm). Low progesterone women had higher heart rates following nicotine patch 
administration than high progesterone/luteal-phase women with average differences between 4 and 12 
bpm. This heart rate increase was accompanied by a significant increase in systolic blood pressure 
following nicotine administration. Differences between the no nicotine and nicotine pretreatment 
conditions were small but consistent: between 4 and 6 mm Hg. Diastolic blood pressure was not 
affected by nicotine pretreatment. There were no differences in blood pressure due to progesterone 
levels/menstrual cycle phase.  
 Int. J. Environ. Res. Public Health 2009, 6          
 
533
Table 2. Physiological Measures: Statistical Results. Separate analyses were performed on 
the time points before the drinking period, and on the time points after drinking. The after 
drinking analyses included the baseline time point before patch administration (-200 
minute time point) and all after- drinking time points. Prog = progesterone factor. 
Heart Rate  Before Drinking  Dose:  F(2, 36)=26.647, p<.001 
    Time:  F(19, 342)=44.451, p<.001 
    Dose x Time:  F(38, 684)=7.097, p<.001 
    Dose x Time x Prog:  F(38, 684)=1.737, p=.004 
  After Drinking  Dose:  F(2, 36)=45.619, p<.001 
    Time:  F(19, 342)=18.917, p<.001 
    Dose x Time:  F(38, 684)=3.924, p<.001 
    Dose x Time x Prog:  F(38, 684)=1.489, p=.031 
Systolic Blood Pressure  Before Drinking  Dose:  F(2, 36)=3.968, p=.028 
    Time:  F(5, 90)=16.314, p<.001 
    Dose x Time:  F(10, 180)=3.129, p=.001 
    Dose x Time x Prog:  F(10, 180)=0.584, p=.826 
  After Drinking  Dose:  F(2, 36)=5.593, p=.008 
    Time:  F(5, 90)=7.048, p<.001 
    Dose x Time:  F(10, 180)=1.493, p=.145 
    Dose x Time x Prog:  F(10, 180)=1.178, p=.308 
Diastolic Blood Pressure  Before Drinking  Dose:  F(2,36)=1.805, p=.179 
   Time:  F(5,90)=2.132,  p=.069 
    Dose x Time:  F(10,180)=0.655, p=.765 
    Dose x Time x Prog:  F(10,180)=0.934, p=.504 
  After Drinking  Dose:  F(2, 36)=7.395, p=.002 
    Time:  F(5, 90)=3.804, p=.004 
    Dose x Time:  F(10, 180)=1.338, p=.069 
    Dose x Time x Prog:  F(10, 180)=0.666, p=.755 
Skin Temperature  Before Drinking  Dose:  F(2, 36)=5.034, p=.012 
    Time:  F(18, 324)=48.240, p<.001 
    Dose x Time:  F(36, 648)=0.800, p=.793 
    Dose x Time x Prog:  F(36, 648)=1.224, p=.064 
  After Drinking  Dose:  F(2, 36)=1.978, p=.153 
    Time:  F(18, 324)=5.636, p<.001 
    Dose x Time:  F(36, 648)=1.496, p=.033 
    Dose x Time x Prog:  F(36, 648)=0.495, p=.995 
 
3.2. Alcohol and combined nicotine-alcohol effects: Subjective measures 
 
Visual analog scales. Except for ratings on the ‘desire to smoke’ scale, nicotine did not produce any 
significant changes on the visual analog scales during pretreatment; ratings on the scale adjectives Int. J. Environ. Res. Public Health 2009, 6          
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remained stable during the pretreatment period regardless of whether participants received nicotine or 
not. Ratings on the ‘desire to smoke’ scale gradually decreased from baseline (when the participants 
first arrived in the laboratory) and were significantly lower at the last assessment before drinking in 
both groups of women and for both the placebo and active nicotine pretreatment conditions [time: F (5, 
90) = 16.621, p<.001].  
An analysis of the peak effects following the alcohol drink revealed significant dose effects for 4 
scales assessing euphoric conditions (Figure 1). Responses following the nicotine-alcohol combination 
were significantly greater than the nicotine alone condition for ‘feel the effects of alcohol’ [F (2, 36) = 
13.179, p<.001], ‘stimulated’ [F (2, 36) = 3.831, p=.031], ‘high’ [F (2, 36) = 7.788, p=.002], and 
‘floating’ [F (2, 36) = 3.344, p=.047]. Additionally, responses on ‘feel effects of alcohol’ for the 
alcohol alone condition were significantly greater than the nicotine alone condition. Responses to 
‘drunk’ were similar to ‘feel effects of alcohol’ and were significantly higher in both alcohol 
conditions in comparison to the nicotine alone condition [F (2, 36) = 8.986, p=.001] (data not shown). 
Although responses from the participants with low progesterone levels were generally lower than the 
high progesterone participants, there were no significant differences between the two groups on these 
measures of subjective alcohol effects. Ratings of ‘desire to smoke a tobacco cigarette’ were 
significantly higher in the alcohol alone condition in comparison to either the nicotine alone or the 
combination drug condition [F (2, 36) = 6.705, p =.003] (data not shown). Progesterone did not alter 
this effect.  
 
Figure 1. Peak effects scores for 4 scales of euphoric effects: A-Feeling Alcohol Effects; 
B-Stimulated; C-High; D-Floating. Participants rated their subjective effects on a 100 point 
scale from 0 – “not at all” to 100 – “extremely”. Columns are averages (± sem) by drug 
condition and progesterone group. *1: Drug condition significantly different from nicotine 
alone (p<.05). *2: Combination drug condition significantly different from nicotine alone 
and alcohol alone (p<.05). 
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a. Self-reported feelings of ‘alcohol effects’. 
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Figure 1. Cont. 
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b. Self-reported feelings of ‘Stimulated’. 
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Three of the scales assessing dysphoric effects showed significant dose effects for the combination 
drug condition (Figure 2). ‘Muddled/confused’ [F (2, 36) = 3.628, p=.037], ‘clumsy’ [F (2, 36) = 
4.568, p=.017], and ‘dizzy’ [F (2, 36) = 4.252, p=.022] ratings were significantly higher following the 
combination drug condition than either the nicotine or alcohol alone conditions. Ratings of ‘nauseous’ 
showed a trend toward higher ratings in the combination condition in comparison to the nicotine alone 
condition [F (2, 36) = 3.0, p=.062]. In addition, ratings on ‘muddled/confused’ and ‘clumsy’ were 
significantly higher in the high progesterone group in comparison to the low progesterone group in the 
drug combination condition.  
 
Figure 2. Peak effect scores for 4 scales of dysphoric effects: A-Muddled/Confused; B-
Clumsy; C-Dizzy; D-Nauseous. Participants rated their subjective effects on a 100 point 
scale from 0 – “not at all” to 100 – “extremely”.  
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a. Self-reported feelings of ‘Muddled/Confused’. 
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b. Self-reported feelings of ‘Clumsy’. 
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Figure 2. Cont. 
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c. Self-reported feelings of ‘Dizzy’. 
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d. Self-reported feelings of ‘Nauseous’. 
Columns are averages (± sem) by drug condition and progesterone group. *2: Combination drug 
condition significantly different from nicotine alone and alcohol alone (p<.05). *3: Significant 
difference between low and high progesterone groups (p<.05). +Statistical trend for combined dose 
different from nicotine alone condition (p=.062) and for difference between progesterone groups 
(p=.068). 
 
Keypad. Self-reported detection of an alcohol effect and the duration of that effect were dependent 
on the administration of alcohol. In the nicotine alone condition (placebo drink), three low 
progesterone women and two high progesterone women reported feeling an alcohol drug effect with 
latency to detection averages of 130.1 ± 75.1 and 165.2 ± 43.3 minutes respectively. The drinking 
session (placebo) occurred at time 30. Following alcohol drinking, participants reported detecting an 
alcohol drug effect significantly faster [F(2, 34)=30.853, p<.001] with 8 of 10 low- progesterone and 
10 out of 10 high progesterone women detecting an alcohol effect in this condition. Latency to Int. J. Environ. Res. Public Health 2009, 6          
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detection times were 57.9 ± 69.5 and 20.5 ± 14.8 minutes respectively. This effect was not altered by 
nicotine pretreatment. In the combined drug condition, 8 out of 9 low progesterone women and 9 out 
of 10 high progesterone women reported detecting an alcohol drug effect with average times of 43.8 ± 
54 and 34.1 ± 52.5 minutes respectively. (Data from one low progesterone participant was lost due to 
equipment problems). Duration of an alcohol drug effect for low- and high progesterone women was 
64.2 ± 50.7 and 80.9 ± 56.2 minutes in the alcohol-alone condition, and 47.9 ± 47.8 and 69.4 ± 52.7 
minutes in the combined nicotine-alcohol condition. Both alcohol conditions were significantly longer 
than the nicotine-alone condition [F(2, 34)=10.942, p<.001]. Progesterone levels did not affect 
detection latencies or duration of effect. Reports of euphoria and dysphoria were low in all conditions 
(between 20 and 30%). Time to onset of these conditions and duration of these conditions when 
reported were not altered by drug condition and were not different between the two progesterone 
groups.  
 
ARCI. Scores for the PCAG (pentobarbital/chlorpromazine/alcohol group--sedation), AMP 
(amphetamine--stimulation), BG (benzedrine group--stimulation), and LSD (lysergic acid 
diethylamide--dysphoria and somatic effects) scales were unaffected by drug administration (data not 
shown). For the MBG scale, scores gradually decreased over the course of the experiment from a high 
at baseline of 2.5 to 1.7 near the end of the session (data not shown). A slight, but non-significant 
increase in MBG scores was observed immediately following alcohol administration but was not dose 
related [dose: F(2, 36)=.709, p=.499; time: F(11, 198)=1.986, p=.032] Overall, high progesterone 
women reported MBG scores 2 to 3 times higher than that of low progesterone women [F(1, 
18)=4.889, p=.040].  
 
3.3. Alcohol and combined nicotine-alcohol effects: Physiologic variables 
 
Heart rate. Nicotine pretreatment significantly increased heart rate. In addition, significant 
increases in heart rate above baseline were observed in all three conditions following drinking (Figure 
3, Table 2). The three dose conditions were significantly different from each other. Increases were 
greatest for the combined nicotine patch-alcohol condition, intermediate for the nicotine alone 
condition and least for the alcohol alone condition. A significant 3-way interaction (dose x time x 
progesterone level) was observed following the drinking procedure indicating the greater heart rate 
changes in the low progesterone women. Analysis of the peak heart rates following drinking revealed 
that heart rates in comparison to baseline increased on the average 14.9 bpm for the alcohol alone 
condition, 21.2 bpm for the nicotine alone condition, and 26.8 bpm for the combination drug condition 
representing increases of 23%, 31% and 39% respectively. Peak rates were observed on individual 
participants between 30 and 90 minutes after drinking.  Int. J. Environ. Res. Public Health 2009, 6          
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Figure 3. Time course of heart rate by drug condition (means ± sem) and progesterone 
levels: A-Low Progesterone; B-High Progesterone/Luteal-Phase women.  Heart rates at 
baseline (-200 minutes) are not significantly different between groups. The nicotine patch 
significantly increased heart rates during the pre-drinking time period (p<.001). For both 
groups after the drinking period, the three drug conditions are significantly different from 
each other (p<.001). The large increase in heart rates at –50 minutes was due to a bathroom 
break given to all subjects. 
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a. Heart rate responses in Low Progesterone women to three drug conditions. 
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b. Heart rate responses in High Progesterone /Luteal-Phase women to three drug conditions. Int. J. Environ. Res. Public Health 2009, 6          
 
540
Blood pressure. Both systolic and diastolic blood pressure were affected similarly: the nicotine 
alone and the nicotine plus alcohol conditions were significantly higher than the alcohol alone 
condition (Table 2). During these conditions, systolic pressure was significantly elevated over baseline 
for one hour. Differences were between 7 and 12 mm Hg. Diastolic pressure was not significantly 
elevated over baseline, but the 30 minute values were higher by between 2 and 3 mm Hg than values 
subsequent to 90 minutes after administration. There were no differences due to progesterone levels. 
 
Skin Temperature. Overall, skin temperature rose during the pretreatment phase, from the beginning 
of the study with an average of 33.8
o C to an average of 35.5
o C at 60 minutes before drinking (Table 
2). Temperatures of participants receiving the active nicotine patch showed significantly less of an 
increase compared to those receiving the placebo patch, although the differences were modest (in the 
range of a half degree Celsius). Following alcohol drinking, temperatures generally remained stable, 
although the temperature of the subjects drinking alcohol decreased slightly in comparison to the 
nicotine alone condition at 80 minutes after ingestion and remained depressed for 30 minutes. 
Differences again were approximately a half degree Celsius. There were no differences in skin 
temperature due to progesterone levels. 
 
3.4. Blood analysis 
 
Blood samples were analyzed for nicotine concentrations before application of the patch to verify 
overnight abstinence and after application of the patch. Nicotine was not detected in any participant, 
except one, at the start of the study day in agreement with refraining from smoking for at least 8 hours. 
The participant who tested positive had a level of 5.6 ng/mL at the start of the session (which is less 
than the 7 ng/mL level set by Marks et al. [40] as evidence of overnight abstinence). Her pretreatment 
data were inspected and found not to differ from other participants’ results. When participants received 
the active patch, nicotine plasma levels averaged between 23 and 25.5 ng/mL at 2.5 hours after 
application and rose slightly to averages between 25.25 and 31.9 ng/mL at the end of the session (6 
hours after application). There were no significant differences in nicotine levels between nicotine alone 
and nicotine plus alcohol drinking sessions, nor were there any differences based on progesterone 
levels/menstrual cycle phase. 
Blood alcohol levels (BAL) rose quickly after drinking, reaching peak concentrations at 50 minutes 
after commencement. Peak concentrations for the alcohol groups averaged between 45 and 55 mg/dL 
(equivalent to 0.045 and 0.055%). Neither nicotine pretreatment nor progesterone levels altered the 
BAL concentration curves. Other standard pharmacokinetic parameters were analyzed: time to 
maximum concentration, elimination half life, and area under the plasma concentration curve. None of 
these measures was significantly altered by nicotine pretreatment and there were no differences due to 
progesterone levels. 
 
4. Discussion 
 
This study shows that alcohol drinking produces significant changes in subjective and physiological 
measures in women, and that some of these effects are increased by nicotine pretreatment. Int. J. Environ. Res. Public Health 2009, 6          
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Furthermore, this study shows that progesterone levels can alter the magnitude of these responses with 
effects greatest for high progesterone/luteal-phase women.  
In the previous study from our laboratory [16], men were studied in the identical paradigm using the 
same nicotine pretreatment patch (21 mg) but including two doses of alcohol (0.4 and 0.7 g/kg). In that 
study, nicotine pretreatment enhanced alcohol effects after both doses. The present study used only the 
lower dose of alcohol and used two  groups of female participants to study the influence of 
progesterone levels. A comparison of the lower alcohol dose effects between men in the previous study 
and the two groups of women in the present study shows many similarities. Increased reports of 
feelings of ‘drunk’, ‘feeling the effects of alcohol’, and ‘desiring to drink alcohol’ after drinking were 
observed after the nicotine condition in both the women in the present study and the men in our 
previous study. However, in contrast to the men in the previous study, the women in this study 
reported an increased feeling of ‘high’, ‘stimulated’, and ‘floating’ after consuming alcohol when 
pretreated with nicotine. Also, in contrast to the men in the previous study, women reported more 
instances of negative effects. Significant increases of ‘muddled/confused’, ‘clumsy’, and ‘dizzy’ were 
also observed. These effects were more predominant in the group of high progesterone women. 
Comparisons of peak subjective reports after the nicotine-alcohol condition show that responses from 
the high progesterone/luteal-phase women are similar to those from the men. In contrast, peak 
responses from the women in the low progesterone group showed the least amount of change, roughly 
half the magnitude of the responses from the men and the high progesterone women. Secondly, women 
overall were more sensitive to the negative effects of nicotine-alcohol combinations than men, and 
these effects are significantly greater in high progesterone/luteal-phase women.  
Studies with human volunteers also have shown that there exists a complex interaction between 
nicotine and alcohol. Perkins et al. [3] demonstrated that a combination of nicotine via nasal spray plus 
alcohol had differential effects in men vs. women. Nicotine reversed the decreases in vigor and arousal 
that alcohol produces in men, whereas in women alcohol alone was not found to decrease vigor and 
arousal, and nicotine significantly increased these effects. Using the nicotine patch which delivers 
nicotine at a slow and sustained rate, Kouri et al. [16] reported that nicotine enhanced several of 
alcohol’s effects in men. Subjective effects of feeling drunk, feeling the effects of alcohol, and desire 
to drink more alcohol were increased with nicotine pretreatment. The present study shows that slow 
delivery of nicotine in abstinent smokers did not produce significant subjective effects by itself, but 
when combined with alcohol, there tended to be an increase in alcohol’s typical responses. The present 
study furthermore shows that these increases are particularly prominent in high progesterone/luteal-
phase women. 
Nicotine and alcohol had additive effects on heart rate but not on blood pressure. Blood pressure 
changes were due to nicotine administration and it was unaltered by the addition of alcohol at the dose 
employed in this study. Previous studies have also studied the effects of these drugs on heart rate and 
blood pressure. Benowitz et al. [41], using higher doses of alcohol (0.5 and 1.0 g/kg), found that 
alcohol alone increased heart rate and systolic blood pressure and that alcohol plus intravenous 
nicotine together produced an additive effect. Perkins et al. [3], also using a slightly higher dose (0.5 
g/kg), found an alcohol-nicotine (via nasal spray) additive effect on heart rate but not on blood 
pressure as increases from baseline under the combined condition were similar to those following 
nicotine alone. Additionally, Perkins et al. [3] did not find any differences between men and women. Int. J. Environ. Res. Public Health 2009, 6          
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Our studies with male and female subjects are consistent with these studies and provide further 
evidence for a heart rate increase by nicotine-alcohol combinations in comparison to either drug alone. 
The direct effects of progesterone on nicotine and/or alcohol’s effects have not been extensively 
studied. Nicotine (via the patch) has been shown to be more effective in relieving symptoms during a 
5-day abstinence period when progesterone levels are high (late luteal phase of the menstrual cycle) 
[42]. Sofuoglu et al. [43] found that progesterone treatments during the follicular phase (when 
progesterone levels are low) reduce cravings and other subjective effects of smoking. The present 
study suggests that progesterone influences responses to nicotine-alcohol combinations. High 
progesterone women showed a greater peak response to both positive and negative subjective effects 
such as feelings of floating, stimulation, confused, and clumsy than the low progesterone women. 
Additionally, high progesterone women reported detecting alcohol effects sooner and for a longer 
period of time although this was not significantly different from the low progesterone women. Several 
studies using nicotine or alcohol alone stand in contrast to the present findings in that subjective and 
physiological responses were not found to differ as a function of menstrual cycle phase. Marks et al. 
[40] found that subjective and physiological responses to nicotine nasal spray were not affected by 
menstrual cycle phase. Analysis of responses on visual analog scale adjectives, and physiological 
measures of heart rate and blood pressure were similar across early follicular, mid-follicular, mid-
luteal, and late luteal phases. An analysis of alcohol’s effects during these same four phases of the 
menstrual cycle also showed no differences on subjective measures (e.g. ARCI, Profile of Mood 
States) and physiological variables (e.g. heart rate, blood pressure) [44]. Other behaviors such as flight 
simulator performance and attention do not change during the menstrual cycle [45-47]. Studies of a 
menstrual cycle phase analysis of nicotine-alcohol combinations are lacking and the present study 
suggests that there are effects not evident when either drug is studied alone.  
An exploration of the effects of nicotine and alcohol combinations on subjective variables and 
physiological measures will help understand how these two commonly used drugs can influence each 
other, shedding light on why the intake of this combination is so often observed. Differences between 
men and women, and the influence of the menstrual cycle hormones in women are important 
considerations in developing a complete picture of drug intake and patterns. The data collected for low 
and high progesterone women indicate that responses to nicotine-alcohol combinations can be highly 
variable. It is interesting to note that in the present study high progesterone/luteal-phase women had 
higher subjective responses to the alcohol-nicotine combination (both positive and negative responses) 
compared to the low progesterone women in spite of lower magnitude increases in heart rate. Larger 
sample sizes may be required to fully assess the influence of menstrual cycle hormones and their 
interactions with subjective and physiological responses. Original sample sizes were computed based 
on reports at the time (e.g. [3]) and previous experience with these measures (e.g. [48]). Results from 
more recent studies of menstrual cycle phase differences (e.g. [33, 44]) and the current study would 
indicate that larger sample sizes are necessary to properly assess the influence of menstrual cycle 
hormones. Several other limitations of the study should be noted. A full within-subjects design where 
women were tested on all three drug combinations in each of two menstrual cycle phases (follicular 
and luteal) was not employed. Only one dose of alcohol was tested as was only one strength of the 
nicotine patch. Additionally, there was no double-placebo condition. These design restrictions were 
employed in an effort to complete the study in a timely manner and to reduce the demands on Int. J. Environ. Res. Public Health 2009, 6          
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individual participants. The results should be viewed with these limitations understood and additional 
studies are necessary to verify the present findings. 
Two other factors should be noted. First, although there was a clear and significant difference in 
progesterone levels between the two groups, the average level in the luteal-phase women of our study 
(7.14 ng/mL) was at the lower end of what has been typically reported (7.5 – 15 ng/mL) during the 
luteal phase of the menstrual cycle (e.g. [23, 42, 44, 49, 50]). Despite this, and the wide range of 
values in our subjects, significant differences emerged between the groups. A more complete 
assessment of nicotine-alcohol interactions may be obtained in future experiments when progesterone 
levels are increased and better controlled. Second, the influences of estrogen were not assessed in this 
study. Participants took several different brands of oral contraceptive medications and the amount of 
estrogen undoubtedly varied. Although the direct, isolated effects of estrogen/estradiol administration 
on responses to alcohol have not been studied in humans, most recent studies indicate that subjective 
responses to alcohol alone do not vary across the menstrual cycle (see review [51]). Our results are 
consistent with those reports. Subjective effects to alcohol alone were similar in both groups. 
Significant phase effects emerged only following nicotine pretreatment. The effects of estrogen alone 
on subjective responses, if any, are believed to be small, but await further experimentation. 
 
5. Conclusions 
 
The present study was accomplished as part of a set of experiments exploring the effects of nicotine 
pretreatment on the effects of several drugs of abuse [16, 36, 37]. They were designed to help 
understand why nicotine is so often used in conjunction with other drugs and have demonstrated that 
nicotine pretreatment does, in fact, alter alcohol’s subjective and physiological effects. Perkins [15] 
has reviewed data to indicate that nicotine increases subjective and physiological responses to alcohol. 
The present study agrees with these results and may contribute additional data on understanding how 
sex differences and menstrual cycle hormones in women are important factors to understanding the 
nature of the nicotine-alcohol interactions. 
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